SlideShare una empresa de Scribd logo
1 de 49
Descargar para leer sin conexión
OVARIAN TUMORS
INTRODUCTION
Dr. Sourav Chowdhury
Senior Resident, IQCMC
MBBS, DGO
NORMAL OVARIES
• Normal size 5 x 3 x 3cm
• Variation in dimensions can result from
– Endogenous hormonal production(varies with age
and menstrual cycle)
– Exogenous substances, including OCs, GnRH
agonists, or ovulation-inducing medication, may
affect size
mesoovariumOvarian Ligament
Free Posterior Border
Ovarian classification and Management
DIFFERENTIAL DIAGNOSIS OF ADNEXAL MASS
ORGAN CYSTIC SOLID
OVARY Functional cyst, Neoplastic cyst,
Benign, Malignant, Endometriosis
Neoplasm
Benign
Malignant
FALLOPIAN TUBES Tubo-ovarian abscess
Hydrosalpinx
Paraovarian cyst
Tubo-ovarian abscess
Ectopic pregnancy
Neoplasm
UTERUS Intrauterine pregnancy in a bicornuate
uterus
Pedunculated or
inteligamentous myoma
BOWEL Sigmoid or caecum distended with gas
or feces
Diverticulitis, Ileitis,
Appendicitis, Colonic cancer
MISCELLANEOUS Distended bladder, Pelvic kidney,
Urachal cyst
Abdominal wall hematoma or
abscess, retroperitoneal
Lifetime Risk of ovarian neoplasm
• A woman has 5–10% lifetime risk of undergoing
surgery for a suspected ovarian neoplasm and
• 13–21% of these will be found to be have an ovarian
malignancy
COMMON OVARIAN TUMOURS
Infancy Pre pubertal Adolescent Reproductive Peri
menopausal
Post
Menopausal
1 Functional
cyst
Functional
cyst
Functional
cyst
Functional cyst Epithelial
ovarian tumor
Neoplastic
ovarian tumor
2. Germ cell
tumor
Germ cell
tumor
Germ cell
tumor
Dermoid Functional cyst Functional
cyst
3. Epithelial
tumor
Epithelial
tumor
Mets
Functional ovarian cysts
• Follicular cysts
• Corpus luteum cysts
• Theca lutein cysts
• Luteomas of pregnancy
 By far the most common clinically detectable
enlargements of the ovary in the reproductive years.
 All are benign and usually asymptomatic.
Ovarian classification and Management
WHO CLASSIFICATION
I. Common Epithelial Tumors:
• Serous tumors
• Mucinous tumors
• Endometrioid tumors
• Clear cell tumors
• Brenner tumors
• Mixed epithelial tumors
• Undifferentiated ca.
• Unclassified epithelial tumors
II. Sex cord tumors:
• Granulosa-stromal cell tumors, theca cell tumors
• Androblastomas
• Gynandroblastomas
• Unclassified
III. Lipid cell tumors
IV. Germ cell tumors:
• Dysgerminoma
• Endodermal sinus tumor
• Embryonal ca.
• Polyembryoma
• Choriocarcinoma
• Teratoma
• Mixed
V. Gonadoblastomas:
• Pure
• Mixed
VI. Soft tissue tumors (not specific to ovary)
VII. Unclassified tumors
VIII. Secondary tumors
IX. Tumor-like conditions
Ovarian classification and Management
CLINICAL PRESENTATION
• Age
• Parity
• Symptoms
• Signs
• On Examinations
– Abdominal
• Inspection
• Palpation
• Percussion
– Pelvic
Benign ovarian neoplasms are indistinguishable clinically from malignant
counterparts
PHYSICAL EXAMINATION
• Abdominal and vaginal examination and the presence
or absence of local lymphadenopathy
• Assess
– Laterality
– Cystic Vs solid
– Mobile Vs fixed
– Smooth Vs irregular
– Ascites
– Cul-de-sac nodules
– Rapid growth rate
COMPLICATIONS
• Torsion
• Intracystic hemorrhage
• Infection
• Rupture
• Pseudomyxoma peritonei
• Malignancy
• Full bladder
• Pregnancy
• Fibroid
• Chocolate cyst
• Encysted peritonitis
• Ascites
• Functional cyst of ovary
Diferrential Diagnosis
INVESTIGATION
Special
• Pattern recognition is superior to all other scores.
• Subjective evaluation of ovarian masses based on pattern
recognition can achieve sensitivity of 88% to 100% and
specificity of 62% to 96%.
• Adding doppler does not seem to yield much improvement in
the diagnostic precision, but increases the confidence with
which a correct diagnosis of benignity or malignancy is made.
TVS
DOPPLER EVALUATION
• Hypoxic tissue in tumors recruit low-resistance, high-flow blood
vessels
• Role in evaluating ovarian mass is controversial – as the ranges of
values of RI,PI,MSV between benign and malignant masses overlap.
PI<1, RI<0.4
• To overcome this, vascular sampling of suspicious areas (papillary
projections, solid areas, thick septations) using both 3D USG and
power doppler both has been evaluated and found effective.
• “Chaotic” vascular pattern in malignancy
OTHER IMAGING MODALITIES
• CT, MRI, PET not recommended in the initial evaluation
• CT scan: evaluating
– LN involvement,
– Omental mets, peritoneal deposits, hepatic mets,
– obstructive uropathy
– or a probable alternate primary site when cancer is suspected based
upon TVS
• MRI : differentiating non adnexal pelvic masses (like leiomyomata),
expensive and inconvenient.
• ACOG GUIDELINES 2007
Differences Benign Malignant
1. Age More common in late
child-bearing age
More common in post-
menopausal age
2. Parity No correlation More with nulliparity or
family H/O
3. Symptoms Gradual growth Rapid growth
4. Signs General cond. Uneffected Cachexia & pallor,
jaundice, LN
5. Per abdomen More or less mobile,
commonly cystic, border
defined and smooth
surface
Liver enlarged, firm and
nodular. SOL- solid &
heterogenous with
restricted mobility,
irregular surface with
probable adhesions
Differences
Simple ultrasound-based rules for the
Sonological Difference
TUMOR MARKERS
Ovarian classification and Management
SENSITIVITY SPECIFICITY PPV NPV
61-90% 71-93% 35-91% 67-90%
CA-
125
Most useful when non-mucinous epithelial cancers are present
Elevated in 80% of patients with epithelial ovarian Ca but only in 50% of patients
with stage I disease
Increased sensitivity in post menopausal women esp. when associated with
relevant clinical and USG findings
Cut-off of 30 u/ml, sensitivity of 81% and specificity of 75%
HE4
• HE4 is a precursor to the epididymal secretory protein E4 and in normal
ovarian tissue, there is minimal gene expression and production of HE4.
• As a single tumor marker, HE4 had the highest sensitivity for detecting
ovarian cancer, especially Stage I disease.
• Combined CA125 and HE4 is a more accurate predictor of malignancy
than either alone or to any other dual combination of markers
• HE4 levels(>70 pM) were found to be elevated in over half of the patients
with ovarian cancer with normal serum CA125 levels (>35 U/ml)
• HE4 when studied in the premenopausal group of patients was able to
discriminate benign tumors from malignancies
Moore et al. / Gynecologic Oncology, 2008
NEW SCORES
• ROMA: Risk of Ovarian Malignancy Algorithm
The dual marker algorithm utilizing HE4 and CA125 to calculate a ROMA value
In patients with stage I and II disease, ROMA achieved a sensitivity of 85.3% compared
with 64.7% for RMI
MOORE ET AL, AJOG 2010
• OVA 1:
FDA approved. Combination of 5 immunoassays
CA 125, transthyrettin, apo lipoprotein A1, transferrin, B2 microglobulin
Sensitivity : 93%, specificity: 43% PPV 42% NPV 93%
COMMUN ONCOL, 2010
Asymptomatic simple cysts
<5cms Likely physiological
(do not require follow up)
5-7 cms Yearly USG
>7cm Require further
imaging/surgical intervention.
RCOG 2011
Ovarian mass in reproductive age group
<5 cms. >/= 5 cms
USG USG
cystic
observation
Complex,
solid,
suspicious
Persistence or progression
surgery
Ovarian mass in childhood:
History and physical examination
Appr. Imaging studies
Simple cyst
- Observe and reassess
Solid or solid cystic
MRI and tumor markers
High suspicion
of malignancy
Low suspicion
of malignancy
Laparotomy laparoscopy
Frozen section
Malignant –
oophorectomy
and staging
Benign - cystectomy
Ovarian cysts in postmenopausal women:
• Post menopausal gonad atrophies to a size of
1.5 X 1 X 0.5cm on average
• Shouldn’t be palpable on pelvic examination.
• Presence of palpable ovary must alert the
possibility of an underlying malignancy.
• Incidence in asymptomatic post menopausal women
–
1.5% by pelvic examination
3.3% to 14.5% by USG.
obstet gynecol survey, 2002
• Causes -10% functional
90% neoplastic (either benign or malignant)
ASSESSMENT
• It is recommended that ovarian cysts in postmenopausal women
should be assessed using CA125 and transvaginal grey scale
sonography.
• There is no routine role yet for Doppler, MRI, CT or PET.
RCOG 2010
SENSITIVITY SPECIFICITY
TVS 89% 73%
CA 125 81% 75%
Ovarian classification and Management
Ovarian classification and Management
RCOG
• Simple, unilateral, unilocular ovarian cysts, less than 5 cm in diameter, have a
low risk of malignancy. It is recommended that, in the presence of a normal
serum CA125 levels, they be managed conservatively.
• Aspiration is not recommended for the management of ovarian cysts in
postmenopausal women.
• It is recommended that a ‘risk of malignancy index’ should be used to select
women for laparoscopic surgery, to be undertaken by a suitably qualified
surgeon.
• It is recommended that laparoscopic management of ovarian cysts in
postmenopausal women should involve oophorectomy (usually bilateral)
rather than cystectomy.
BORDERLINE OVARIAN TUMORS
They were not separately classified by the FIGO and the WHO
until the early 1970s.
• Borderline tumors make up approximately 15% of all
epithelial ovarian tumors.
• The mean age of occurrence is approximately 10 years
younger than that of women with frankly malignant ovarian
cancer.
Tumour subtypes
• 2 major histological tumor subtypes
– Serous(50%)
• (bilateral in 30%)
• Could be associated with extraovarian lesion : implants(35%)
– Mucinous (46%)
• Mucinous tumors do not have a clearly defined origin.
– Substantial information indicates that many tumors may
actually originate from the appendix; thus, this organ
should be removed at the time of surgery.
Ovarian classification and Management
Histology and Cytology
• According to Dietel and Hauptmann, the histology of borderline tumors is
characterized by the following features:
– Epithelial multi-layering of more than 4 cell layers
– Not more than 4 mitoses per 10 high-power field (HPF)
– Mild nuclear atypia
– Increase in nuclear/cytoplasmic ratio
– Slight to complex branching of epithelial papillae and pseudopapillae
– Epithelial budding and cell detachment into the lumen
– No destructive stromal invasion - A major component in
differentiating malignant from borderline tumors
TUMOR STAGING
• Comprehensive staging : of significant prognostic
value and is performed surgically
• Borderline ovarian tumors are staged according to
the FIGO classification of ovarian cancer.
International Federation Of Obstetrics And Gynecology
(FIGO) staging
FIGO stage Definition
I Tumor confined to the ovary
II Peritoneal implants within the pelvis
III
Peritoneal implants beyond the pelvis,
Positive lymph nodes, or both
IV
Liver parenchyma involvement, or tumor
beyond the peritoneal cavity
TREATMENT
* No further chemotherapy (in all stages.)
Summary
Ovarian Mass
Reproductive Age
<45yrs
Peri/Postmenopausal
3-5cm >5-7cm >=7cm
Do
Nothing
Follow-up
MRI or
Surgery
RCOG guidelines-62 &34;2011 & 2010
TVS if not performed & CA-125
Calculate RMI
RMI<25 RMI>25-250 RMI>250
Simple U/L <5cm
& CA-125 <30
Other cyst
F/U with TVS & CA-125
4monthly / 1yr
Laraoscopic
removal
Laparoscopy
or laparotomy
in Cancer unit
Laparotomy
in other Sp.
Centre

Más contenido relacionado

La actualidad más candente

Management of abnormal cervical smear
Management of abnormal cervical smearManagement of abnormal cervical smear
Management of abnormal cervical smearchaimingcheng
 
Approach to post menopausal bleeding
Approach to post menopausal bleeding Approach to post menopausal bleeding
Approach to post menopausal bleeding Niranjan Chavan
 
Classification of ovarian tumors
Classification of ovarian tumorsClassification of ovarian tumors
Classification of ovarian tumorsDr Anusha Rao P
 
Gynecologic Tumor Markers
Gynecologic  Tumor  MarkersGynecologic  Tumor  Markers
Gynecologic Tumor Markerswaleed shehadat
 
Palm coein clasification
Palm coein clasificationPalm coein clasification
Palm coein clasificationnermine amin
 
Manchester repair (Fothergill’s Operation)
Manchester repair (Fothergill’s Operation)Manchester repair (Fothergill’s Operation)
Manchester repair (Fothergill’s Operation)Yapa
 
Endometrial hyperplasia
Endometrial hyperplasiaEndometrial hyperplasia
Endometrial hyperplasiaOsama Warda
 
gestational trophoblastic disease GTD
gestational trophoblastic disease GTDgestational trophoblastic disease GTD
gestational trophoblastic disease GTDOsama Warda
 
Post menopausal bleeding
Post menopausal bleedingPost menopausal bleeding
Post menopausal bleedingdr.hafsa asim
 
Laparoscopic Tubal Recanalization Mob: 7289915430, www.drpradeepgarg
Laparoscopic Tubal Recanalization  Mob: 7289915430, www.drpradeepgargLaparoscopic Tubal Recanalization  Mob: 7289915430, www.drpradeepgarg
Laparoscopic Tubal Recanalization Mob: 7289915430, www.drpradeepgargPradeep Garg
 
OPERATIONS FOR NULLIPAROUS PROLAPSE AND VAGINAL VAULT PROLAPSE, Mob: 7289915...
OPERATIONS FOR NULLIPAROUS PROLAPSE AND VAGINAL VAULT PROLAPSE,  Mob: 7289915...OPERATIONS FOR NULLIPAROUS PROLAPSE AND VAGINAL VAULT PROLAPSE,  Mob: 7289915...
OPERATIONS FOR NULLIPAROUS PROLAPSE AND VAGINAL VAULT PROLAPSE, Mob: 7289915...Pradeep Garg
 
Border line ovarian tumours
Border line ovarian tumoursBorder line ovarian tumours
Border line ovarian tumoursnermine amin
 
gynaecology.Primary amenorrhea.(dr.sundus)
gynaecology.Primary amenorrhea.(dr.sundus)gynaecology.Primary amenorrhea.(dr.sundus)
gynaecology.Primary amenorrhea.(dr.sundus)student
 
Cervical and broad ligament fibroid
Cervical and broad ligament fibroidCervical and broad ligament fibroid
Cervical and broad ligament fibroidNiranjan Chavan
 

La actualidad más candente (20)

Management of abnormal cervical smear
Management of abnormal cervical smearManagement of abnormal cervical smear
Management of abnormal cervical smear
 
Asherman syndrome
Asherman syndromeAsherman syndrome
Asherman syndrome
 
Approach to post menopausal bleeding
Approach to post menopausal bleeding Approach to post menopausal bleeding
Approach to post menopausal bleeding
 
OVARIAN TUMOURS
OVARIAN TUMOURSOVARIAN TUMOURS
OVARIAN TUMOURS
 
Classification of ovarian tumors
Classification of ovarian tumorsClassification of ovarian tumors
Classification of ovarian tumors
 
Gynecologic Tumor Markers
Gynecologic  Tumor  MarkersGynecologic  Tumor  Markers
Gynecologic Tumor Markers
 
ENDOMETRIAL CANCER
ENDOMETRIAL CANCERENDOMETRIAL CANCER
ENDOMETRIAL CANCER
 
Palm coein clasification
Palm coein clasificationPalm coein clasification
Palm coein clasification
 
Manchester repair (Fothergill’s Operation)
Manchester repair (Fothergill’s Operation)Manchester repair (Fothergill’s Operation)
Manchester repair (Fothergill’s Operation)
 
Endometrial hyperplasia
Endometrial hyperplasiaEndometrial hyperplasia
Endometrial hyperplasia
 
Postmenopausal bleeding for undergraduate
Postmenopausal bleeding for undergraduatePostmenopausal bleeding for undergraduate
Postmenopausal bleeding for undergraduate
 
gestational trophoblastic disease GTD
gestational trophoblastic disease GTDgestational trophoblastic disease GTD
gestational trophoblastic disease GTD
 
Post menopausal bleeding
Post menopausal bleedingPost menopausal bleeding
Post menopausal bleeding
 
myomectomy
myomectomymyomectomy
myomectomy
 
Laparoscopic Tubal Recanalization Mob: 7289915430, www.drpradeepgarg
Laparoscopic Tubal Recanalization  Mob: 7289915430, www.drpradeepgargLaparoscopic Tubal Recanalization  Mob: 7289915430, www.drpradeepgarg
Laparoscopic Tubal Recanalization Mob: 7289915430, www.drpradeepgarg
 
OPERATIONS FOR NULLIPAROUS PROLAPSE AND VAGINAL VAULT PROLAPSE, Mob: 7289915...
OPERATIONS FOR NULLIPAROUS PROLAPSE AND VAGINAL VAULT PROLAPSE,  Mob: 7289915...OPERATIONS FOR NULLIPAROUS PROLAPSE AND VAGINAL VAULT PROLAPSE,  Mob: 7289915...
OPERATIONS FOR NULLIPAROUS PROLAPSE AND VAGINAL VAULT PROLAPSE, Mob: 7289915...
 
Border line ovarian tumours
Border line ovarian tumoursBorder line ovarian tumours
Border line ovarian tumours
 
gynaecology.Primary amenorrhea.(dr.sundus)
gynaecology.Primary amenorrhea.(dr.sundus)gynaecology.Primary amenorrhea.(dr.sundus)
gynaecology.Primary amenorrhea.(dr.sundus)
 
Liver disease in pregnancy
Liver disease in pregnancyLiver disease in pregnancy
Liver disease in pregnancy
 
Cervical and broad ligament fibroid
Cervical and broad ligament fibroidCervical and broad ligament fibroid
Cervical and broad ligament fibroid
 

Similar a Ovarian classification and Management

Similar a Ovarian classification and Management (20)

Management of ovarian cyst.pdf
Management of ovarian cyst.pdfManagement of ovarian cyst.pdf
Management of ovarian cyst.pdf
 
Ca endometrium
Ca endometriumCa endometrium
Ca endometrium
 
Saving uterus saving ovary
Saving uterus saving ovarySaving uterus saving ovary
Saving uterus saving ovary
 
Adnexal Masses
Adnexal MassesAdnexal Masses
Adnexal Masses
 
Genital tuberculosis- a view
Genital tuberculosis- a view Genital tuberculosis- a view
Genital tuberculosis- a view
 
Ovarian cancer
Ovarian cancerOvarian cancer
Ovarian cancer
 
Ca endometrium-1.pptx
Ca endometrium-1.pptxCa endometrium-1.pptx
Ca endometrium-1.pptx
 
caendometrium-1-220817052735-f5d0c990.pdf
caendometrium-1-220817052735-f5d0c990.pdfcaendometrium-1-220817052735-f5d0c990.pdf
caendometrium-1-220817052735-f5d0c990.pdf
 
Cervical cancer ppt
Cervical cancer pptCervical cancer ppt
Cervical cancer ppt
 
FMIC PRESENTATION1 (OVARIAN CANCER).pptx
FMIC PRESENTATION1 (OVARIAN CANCER).pptxFMIC PRESENTATION1 (OVARIAN CANCER).pptx
FMIC PRESENTATION1 (OVARIAN CANCER).pptx
 
Ovarian tumor in children and adolscent
Ovarian tumor in children and adolscentOvarian tumor in children and adolscent
Ovarian tumor in children and adolscent
 
Screening in Gynecology
Screening in GynecologyScreening in Gynecology
Screening in Gynecology
 
An apporach to ovarian pathology
An apporach to ovarian pathologyAn apporach to ovarian pathology
An apporach to ovarian pathology
 
mati
matimati
mati
 
Post Menopausal Bleeding
Post Menopausal BleedingPost Menopausal Bleeding
Post Menopausal Bleeding
 
Cin&cancer cervix undergraduate
Cin&cancer cervix undergraduateCin&cancer cervix undergraduate
Cin&cancer cervix undergraduate
 
Ovarian tumors
Ovarian tumorsOvarian tumors
Ovarian tumors
 
Ovariancancer chandni
Ovariancancer chandniOvariancancer chandni
Ovariancancer chandni
 
Pgp ovarain case
Pgp ovarain casePgp ovarain case
Pgp ovarain case
 
Female Genital Tract Pathology
Female Genital Tract PathologyFemale Genital Tract Pathology
Female Genital Tract Pathology
 

Más de Sourav Chowdhury

Más de Sourav Chowdhury (13)

Von willebrand disease
Von willebrand diseaseVon willebrand disease
Von willebrand disease
 
Adaptive immunity
Adaptive immunityAdaptive immunity
Adaptive immunity
 
Immune system preliminary
Immune system preliminaryImmune system preliminary
Immune system preliminary
 
Extracorporeal membrane oxygenation
Extracorporeal membrane oxygenationExtracorporeal membrane oxygenation
Extracorporeal membrane oxygenation
 
Rbc Structure and Physiology
Rbc Structure and PhysiologyRbc Structure and Physiology
Rbc Structure and Physiology
 
Ectopic pregnancy
Ectopic pregnancyEctopic pregnancy
Ectopic pregnancy
 
Preterm labour and new management guidelines
Preterm labour and new management guidelinesPreterm labour and new management guidelines
Preterm labour and new management guidelines
 
Obstetric forceps and complication
Obstetric forceps and complicationObstetric forceps and complication
Obstetric forceps and complication
 
Overview on contraception
Overview on contraceptionOverview on contraception
Overview on contraception
 
Pelvic organ prolapse
Pelvic organ prolapsePelvic organ prolapse
Pelvic organ prolapse
 
Management of cin
Management of cinManagement of cin
Management of cin
 
Hormonal contraceptives
Hormonal contraceptivesHormonal contraceptives
Hormonal contraceptives
 
Female sterilisation
Female sterilisationFemale sterilisation
Female sterilisation
 

Último

SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)1922Jaygohel
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfrg0000009
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 

Último (20)

SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdf
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 

Ovarian classification and Management

  • 1. OVARIAN TUMORS INTRODUCTION Dr. Sourav Chowdhury Senior Resident, IQCMC MBBS, DGO
  • 2. NORMAL OVARIES • Normal size 5 x 3 x 3cm • Variation in dimensions can result from – Endogenous hormonal production(varies with age and menstrual cycle) – Exogenous substances, including OCs, GnRH agonists, or ovulation-inducing medication, may affect size
  • 5. DIFFERENTIAL DIAGNOSIS OF ADNEXAL MASS ORGAN CYSTIC SOLID OVARY Functional cyst, Neoplastic cyst, Benign, Malignant, Endometriosis Neoplasm Benign Malignant FALLOPIAN TUBES Tubo-ovarian abscess Hydrosalpinx Paraovarian cyst Tubo-ovarian abscess Ectopic pregnancy Neoplasm UTERUS Intrauterine pregnancy in a bicornuate uterus Pedunculated or inteligamentous myoma BOWEL Sigmoid or caecum distended with gas or feces Diverticulitis, Ileitis, Appendicitis, Colonic cancer MISCELLANEOUS Distended bladder, Pelvic kidney, Urachal cyst Abdominal wall hematoma or abscess, retroperitoneal
  • 6. Lifetime Risk of ovarian neoplasm • A woman has 5–10% lifetime risk of undergoing surgery for a suspected ovarian neoplasm and • 13–21% of these will be found to be have an ovarian malignancy
  • 7. COMMON OVARIAN TUMOURS Infancy Pre pubertal Adolescent Reproductive Peri menopausal Post Menopausal 1 Functional cyst Functional cyst Functional cyst Functional cyst Epithelial ovarian tumor Neoplastic ovarian tumor 2. Germ cell tumor Germ cell tumor Germ cell tumor Dermoid Functional cyst Functional cyst 3. Epithelial tumor Epithelial tumor Mets
  • 8. Functional ovarian cysts • Follicular cysts • Corpus luteum cysts • Theca lutein cysts • Luteomas of pregnancy  By far the most common clinically detectable enlargements of the ovary in the reproductive years.  All are benign and usually asymptomatic.
  • 11. I. Common Epithelial Tumors: • Serous tumors • Mucinous tumors • Endometrioid tumors • Clear cell tumors • Brenner tumors • Mixed epithelial tumors • Undifferentiated ca. • Unclassified epithelial tumors
  • 12. II. Sex cord tumors: • Granulosa-stromal cell tumors, theca cell tumors • Androblastomas • Gynandroblastomas • Unclassified
  • 13. III. Lipid cell tumors IV. Germ cell tumors: • Dysgerminoma • Endodermal sinus tumor • Embryonal ca. • Polyembryoma • Choriocarcinoma • Teratoma • Mixed
  • 14. V. Gonadoblastomas: • Pure • Mixed VI. Soft tissue tumors (not specific to ovary) VII. Unclassified tumors VIII. Secondary tumors IX. Tumor-like conditions
  • 16. CLINICAL PRESENTATION • Age • Parity • Symptoms • Signs • On Examinations – Abdominal • Inspection • Palpation • Percussion – Pelvic Benign ovarian neoplasms are indistinguishable clinically from malignant counterparts
  • 17. PHYSICAL EXAMINATION • Abdominal and vaginal examination and the presence or absence of local lymphadenopathy • Assess – Laterality – Cystic Vs solid – Mobile Vs fixed – Smooth Vs irregular – Ascites – Cul-de-sac nodules – Rapid growth rate
  • 18. COMPLICATIONS • Torsion • Intracystic hemorrhage • Infection • Rupture • Pseudomyxoma peritonei • Malignancy
  • 19. • Full bladder • Pregnancy • Fibroid • Chocolate cyst • Encysted peritonitis • Ascites • Functional cyst of ovary Diferrential Diagnosis
  • 21. • Pattern recognition is superior to all other scores. • Subjective evaluation of ovarian masses based on pattern recognition can achieve sensitivity of 88% to 100% and specificity of 62% to 96%. • Adding doppler does not seem to yield much improvement in the diagnostic precision, but increases the confidence with which a correct diagnosis of benignity or malignancy is made. TVS
  • 22. DOPPLER EVALUATION • Hypoxic tissue in tumors recruit low-resistance, high-flow blood vessels • Role in evaluating ovarian mass is controversial – as the ranges of values of RI,PI,MSV between benign and malignant masses overlap. PI<1, RI<0.4 • To overcome this, vascular sampling of suspicious areas (papillary projections, solid areas, thick septations) using both 3D USG and power doppler both has been evaluated and found effective. • “Chaotic” vascular pattern in malignancy
  • 23. OTHER IMAGING MODALITIES • CT, MRI, PET not recommended in the initial evaluation • CT scan: evaluating – LN involvement, – Omental mets, peritoneal deposits, hepatic mets, – obstructive uropathy – or a probable alternate primary site when cancer is suspected based upon TVS • MRI : differentiating non adnexal pelvic masses (like leiomyomata), expensive and inconvenient. • ACOG GUIDELINES 2007
  • 24. Differences Benign Malignant 1. Age More common in late child-bearing age More common in post- menopausal age 2. Parity No correlation More with nulliparity or family H/O 3. Symptoms Gradual growth Rapid growth 4. Signs General cond. Uneffected Cachexia & pallor, jaundice, LN 5. Per abdomen More or less mobile, commonly cystic, border defined and smooth surface Liver enlarged, firm and nodular. SOL- solid & heterogenous with restricted mobility, irregular surface with probable adhesions Differences
  • 25. Simple ultrasound-based rules for the Sonological Difference
  • 28. SENSITIVITY SPECIFICITY PPV NPV 61-90% 71-93% 35-91% 67-90% CA- 125 Most useful when non-mucinous epithelial cancers are present Elevated in 80% of patients with epithelial ovarian Ca but only in 50% of patients with stage I disease Increased sensitivity in post menopausal women esp. when associated with relevant clinical and USG findings Cut-off of 30 u/ml, sensitivity of 81% and specificity of 75%
  • 29. HE4 • HE4 is a precursor to the epididymal secretory protein E4 and in normal ovarian tissue, there is minimal gene expression and production of HE4. • As a single tumor marker, HE4 had the highest sensitivity for detecting ovarian cancer, especially Stage I disease. • Combined CA125 and HE4 is a more accurate predictor of malignancy than either alone or to any other dual combination of markers • HE4 levels(>70 pM) were found to be elevated in over half of the patients with ovarian cancer with normal serum CA125 levels (>35 U/ml) • HE4 when studied in the premenopausal group of patients was able to discriminate benign tumors from malignancies Moore et al. / Gynecologic Oncology, 2008
  • 30. NEW SCORES • ROMA: Risk of Ovarian Malignancy Algorithm The dual marker algorithm utilizing HE4 and CA125 to calculate a ROMA value In patients with stage I and II disease, ROMA achieved a sensitivity of 85.3% compared with 64.7% for RMI MOORE ET AL, AJOG 2010 • OVA 1: FDA approved. Combination of 5 immunoassays CA 125, transthyrettin, apo lipoprotein A1, transferrin, B2 microglobulin Sensitivity : 93%, specificity: 43% PPV 42% NPV 93% COMMUN ONCOL, 2010
  • 31. Asymptomatic simple cysts <5cms Likely physiological (do not require follow up) 5-7 cms Yearly USG >7cm Require further imaging/surgical intervention. RCOG 2011
  • 32. Ovarian mass in reproductive age group <5 cms. >/= 5 cms USG USG cystic observation Complex, solid, suspicious Persistence or progression surgery
  • 33. Ovarian mass in childhood: History and physical examination Appr. Imaging studies Simple cyst - Observe and reassess Solid or solid cystic MRI and tumor markers High suspicion of malignancy Low suspicion of malignancy Laparotomy laparoscopy Frozen section Malignant – oophorectomy and staging Benign - cystectomy
  • 34. Ovarian cysts in postmenopausal women: • Post menopausal gonad atrophies to a size of 1.5 X 1 X 0.5cm on average • Shouldn’t be palpable on pelvic examination. • Presence of palpable ovary must alert the possibility of an underlying malignancy.
  • 35. • Incidence in asymptomatic post menopausal women – 1.5% by pelvic examination 3.3% to 14.5% by USG. obstet gynecol survey, 2002 • Causes -10% functional 90% neoplastic (either benign or malignant)
  • 36. ASSESSMENT • It is recommended that ovarian cysts in postmenopausal women should be assessed using CA125 and transvaginal grey scale sonography. • There is no routine role yet for Doppler, MRI, CT or PET. RCOG 2010 SENSITIVITY SPECIFICITY TVS 89% 73% CA 125 81% 75%
  • 39. RCOG • Simple, unilateral, unilocular ovarian cysts, less than 5 cm in diameter, have a low risk of malignancy. It is recommended that, in the presence of a normal serum CA125 levels, they be managed conservatively. • Aspiration is not recommended for the management of ovarian cysts in postmenopausal women. • It is recommended that a ‘risk of malignancy index’ should be used to select women for laparoscopic surgery, to be undertaken by a suitably qualified surgeon. • It is recommended that laparoscopic management of ovarian cysts in postmenopausal women should involve oophorectomy (usually bilateral) rather than cystectomy.
  • 41. They were not separately classified by the FIGO and the WHO until the early 1970s. • Borderline tumors make up approximately 15% of all epithelial ovarian tumors. • The mean age of occurrence is approximately 10 years younger than that of women with frankly malignant ovarian cancer.
  • 42. Tumour subtypes • 2 major histological tumor subtypes – Serous(50%) • (bilateral in 30%) • Could be associated with extraovarian lesion : implants(35%) – Mucinous (46%) • Mucinous tumors do not have a clearly defined origin. – Substantial information indicates that many tumors may actually originate from the appendix; thus, this organ should be removed at the time of surgery.
  • 44. Histology and Cytology • According to Dietel and Hauptmann, the histology of borderline tumors is characterized by the following features: – Epithelial multi-layering of more than 4 cell layers – Not more than 4 mitoses per 10 high-power field (HPF) – Mild nuclear atypia – Increase in nuclear/cytoplasmic ratio – Slight to complex branching of epithelial papillae and pseudopapillae – Epithelial budding and cell detachment into the lumen – No destructive stromal invasion - A major component in differentiating malignant from borderline tumors
  • 45. TUMOR STAGING • Comprehensive staging : of significant prognostic value and is performed surgically • Borderline ovarian tumors are staged according to the FIGO classification of ovarian cancer.
  • 46. International Federation Of Obstetrics And Gynecology (FIGO) staging FIGO stage Definition I Tumor confined to the ovary II Peritoneal implants within the pelvis III Peritoneal implants beyond the pelvis, Positive lymph nodes, or both IV Liver parenchyma involvement, or tumor beyond the peritoneal cavity
  • 48. * No further chemotherapy (in all stages.)
  • 49. Summary Ovarian Mass Reproductive Age <45yrs Peri/Postmenopausal 3-5cm >5-7cm >=7cm Do Nothing Follow-up MRI or Surgery RCOG guidelines-62 &34;2011 & 2010 TVS if not performed & CA-125 Calculate RMI RMI<25 RMI>25-250 RMI>250 Simple U/L <5cm & CA-125 <30 Other cyst F/U with TVS & CA-125 4monthly / 1yr Laraoscopic removal Laparoscopy or laparotomy in Cancer unit Laparotomy in other Sp. Centre

Notas del editor

  1. The morphology index (MI) presently used in the University of Kentucky Ovarian Cancer Screening Trial was published initially by Ueland and colleagues and is illustrated in Figure 49.3. Both morphologic complexity and tumor volume, as calculated by the prolate ellipsoid formula, were related directly to the risk of malignancy Morphologic abnormalities were easy to categorize, and interobserver variation was minimal. Risk of malignancy varied from 0.3% in ovarian tumors with a MI of <5 to 84% in tumors with a MI >=8. Using a MI >=5 as indicative of malignancy, the following statistical parameters were observed: sensitivity 0.981, specificity 0.808, PPV 0.409, and NPV 0.997. Therefore, morphologic indexing is a relatively accurate and cost-effective method to predict risk of malignancy in an ovarian tumor.
  2. Using these rules the reported sensitivity was 95%, specificity 91%, positive likelihood ratio of 10.37 and negative likelihood ratio of 0.06.
  3. Wenever possible conservative or minimally invasive surgery is preferred to preserve endocrine and reproductive function.
  4. BOTs form a separate entity within the group of ovarian tumours
  5. BOTs can be divided according to their epithelial characteristics as serous (50%),mucinous (46%), and mixed, endometrioid, clear cell, or Brenner tumors (3.9%). Serous BOTs are bilateral in 30% of patients and can be associated with extraovarian lesions (so-called implants) in 35%. These implants can be invasive or noninvasive depending on their microscopic appearance, which will in turn influence therapeutic options. Mucinous BOTs are classified as intestinal (85%) or endocervical/Mullerian type (15%) depending on the nature of the epithelial lining. They can be associated with pseudomyxoma peritonei (10%), necessitating a thorough investigation of the GI tract with special attention to the appendix because this can be the primary tumor origin. Presenting symptoms of borderline ovarian tumors Borderline tumors, as with other ovarian tumors, are difficult to detect clinically until they are advanced in size or stage. In one study, the most common presenting symptoms were abdominal pain, increasing girth or abdominal distention, and abdominal mass. Approximately 23% of patients were asymptomatic.
  6. Without comprehensive surgical staging, the prognosis for an individual patient is difficult to predict. Many clinicians group stages II-IV together for prognostic consideration. Important component is description of the type of implants, as these have significant prognostic value. Preoperatively, borderline tumors are often presumed to be either benign or malignant ovarian masses; however, as with other ovarian masses, staging is performed surgically. Many sources recommend complete staging if a borderline tumor is found. Current guidelines include biopsy specimens of the pelvic peritoneum (cul-de-sac, pelvic wall, and bladder peritoneum), abdominal peritoneum (paracolic gutters and diaphragmatic surfaces), omentum, intestinal serosa and mesentery, and retroperitoneal lymph nodes (pelvic and para-aortic).
  7. Surgical removal of BOTs is the cornerstone in the management of BOTs, but a lot of debate exists on the extent of the staging procedure and the surgical approach. Lately, the use of laparoscopy and conservative surgery, which is defined as surgery with complete staging but with preservation of the uterus and at least part of one ovary (Fig 1), is gaining popularity. However, the question arises about whether this management is appropriate or whether we should be more cautious.